He holds a Ph.D. in pharmaceutical sciences from the University of Tokyo and is a licensed pharmacist. Prior to joining UTEC in October 2013, he worked as a consultant at Mitsubishi Research Institute. Currently serving as a Partner and Board Director, he oversees venture investments and provides management support primarily in the life sciences sector for seed and early-stage startups. He has played a key role in investments in companies such as OriCiro Genomics, Inc. (acquired by Moderna, Inc.) and Repertoire Genesis, Inc. (acquired by Eurofins Scientific SE). In recognition of his contributions, he was awarded the Encouragement Award for Venture Capitalists at the 23rd Japan Venture Awards in 2023.

What I expect of LINK-J

I'm very happy to work as a supporter for LINK-J to create platforms for new life-science industries. I'm looking forward to further accelerating open innovation across countries and fields through LINK-J initiatives.

Message to LINK-J Special Members

I hope that we will be able to pioneer frontiers of new industries with LINK-J members.